USANA Health Sciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US90328M1071
USD
19.61
-0.6 (-2.97%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About USANA Health Sciences, Inc. stock-summary
stock-summary
USANA Health Sciences, Inc.
Pharmaceuticals & Biotechnology
USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia. Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year. Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.
Company Coordinates stock-summary
Company Details
3838 W Parkway Blvd , SALT LAKE CITY UT : 84120-6336
stock-summary
Tel: 1 801 9547100
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 53 Schemes (26.47%)

Foreign Institutions

Held by 83 Foreign Institutions (4.75%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Kevin Guest
Chairman of the Board, Chief Executive Officer
Mr. Gilbert Fuller
Lead Independent Director
Mr. Robert Anciaux
Senior Director
Mr. John Fleming
Director
Ms. Peggie Pelosi
Independent Director
Mr. Feng Peng
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
236 Million
(Quarterly Results - Jun 2025)
Net Profit:
10 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 565 Million (Micro Cap)

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.28

stock-summary
Return on Equity

6.56%

stock-summary
Price to Book

1.06